PMEF
PTCT icon

Point72 Middle East FZE’s PTC Therapeutics PTCT Stock Holding History

Point72 Middle East FZE’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-38,401
Closed -$861K – 1808
2023
Q3 		$861K Sell
38,401
-5,941
-13% -$221K 0.03% 623
2023
Q2 		$1.8M Buy
+44,342
New +$2.17M 0.05% 402

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Middle East FZE's PTCT Position: Q4 2023 in Review

Point72 Middle East FZE sold out of PTC Therapeutics (PTCT) in Q4 2023, closing a stake of 38,401 shares — an estimated $861K sold.

Point72 Middle East FZE first reported a position in PTCT in Q2 2023 and held it in 2 quarters. The position peaked at $1.8M in Q2 2023. 172 funds tracked by Wall St. Rank hold PTCT as of Q4 2023.

  • Point72 Middle East FZE reported no remaining PTC Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 38,401 PTC Therapeutics shares in Q4 2023, an estimated $861K.
  • Point72 Middle East FZE first reported a position in PTC Therapeutics in Q2 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's PTC Therapeutics position peaked at $1.8M in Q2 2023.
  • 172 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.